Cryosite (CTE.AX) Stock Price
Cryosite Price
Over the last 19 years Cryosite grew revenue by 6.9% annually, reaching 16.70 M AUD. Earnings per share have grown at 4.1% per year over the last 19 years. For Cryosite, the net margin of 13.4% is up versus 11.6% a few years ago. At today's price the dividend yield works out to roughly 1.64%. The payout ratio is around 91% of earnings. The dividend has grown at 5.5% per year over the past 13 years.
Cryosite stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Cryosite business model & stock analysis
Frequently asked questions about Cryosite
The business model of Cryosite Ltd focuses on providing biobanking and cell therapy services. Cryosite specializes in the collection, storage, and distribution of human biological samples such as cord blood, tissue, and cells for medical and research purposes. The company allows individuals and families to preserve cord blood stem cells for potential future use in regenerative medicine. Cryosite also offers cell therapy manufacturing services to support personalized medicine and clinical trials. With its expertise and advanced technology, Cryosite aims to contribute to advancements in medical treatments and research, offering peace of mind to those seeking to preserve their biological materials.
Cryosite Ltd is primarily active in the biomedical and life sciences industries.
The main competitors of Cryosite Ltd in the market are companies like Stemlife, Singapore Cord Blood Bank, and CordLife Group Limited.
Cryosite Ltd, a reputable Australian company, has an intriguing history and background. Established in 2000, Cryosite has played a pivotal role in the field of biomedical services. The company specializes in secure storage and transportation of precious biological samples, supporting medical research, clinical trials, and stem cell transplant programs. With state-of-the-art facilities and stringent quality control measures, Cryosite has gained recognition as a trusted partner for numerous healthcare institutions and research organizations globally. Over the years, Cryosite Ltd has showcased its expertise in preserving and managing these life-changing resources, contributing significantly to advancements in healthcare and cutting-edge research.
Cryosite Ltd has achieved several significant milestones. Firstly, the company successfully established itself as a leading provider of comprehensive storage solutions for stem cells, reproductive tissues, and cord blood in Australia. Additionally, Cryosite Ltd expanded its services by offering advanced cryopreservation techniques, ensuring the long-term viability of stored materials. The company's commitment to quality led to accreditation by the Therapeutic Goods Administration (TGA) and attainment of ISO 9001 certification. Furthermore, Cryosite Ltd expanded its client base, attracting partnerships with major healthcare institutions and research organizations. These milestones demonstrate Cryosite Ltd's success in delivering trusted and state-of-the-art cryogenic storage services to its clients.
Cryosite Ltd primarily operates in Australia and New Zealand.
Cryosite Ltd is a leading company that values integrity, reliability, and innovation. With a strong corporate philosophy focused on providing premium services and solutions in the field of biobanking and reproductive services, Cryosite is committed to excellence. The company strives to ensure the utmost trust and transparency in all its operations, delivering high-quality cryopreservation services, cord blood banking, and stem cell research facilities. Cryosite Ltd continuously pushes boundaries through cutting-edge technology and strategic partnerships, aiming to meet the evolving needs of its customers and make a positive impact in the healthcare industry.
Converted at the current exchange rate, the Cryosite share trades at 0.77 EUR (1.22 AUD).
The Cryosite share (CTE.AX) is listed on 1 stock exchanges, including: ASX (CTE.AX).
Cryosite Ltd is an Australian company that has been operating in the field of biological material storage for over 15 years. With a wide range of services and products, the company has established itself as a leading provider of cryo-storage solutions in Australia.
The revenue of Cryosite is 16.70 M AUD. This figure is based on current financial data and reflects the company's business performance.
The profit of Cryosite is 2.24 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Cryosite is currently 28.49. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Cryosite stock.
The price-to-sales ratio (P/S) of Cryosite is currently 3.81. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Cryosite stock.
The Eulerpool Quality Score for Cryosite is 5/10.
The ISIN of Cryosite is AU000000CTE1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Cryosite is 621943. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Cryosite is CTE.AX. The ticker symbol is used to trade Cryosite shares on the stock exchange.
Cryosite stock
Cryosite Peer Group
Cryosite Ticker
Cryosite FIGI
All fundamentals and in-depth analysis of Cryosite
Our stock analysis for Cryosite stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cryosite. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.